ALLO — Allogene Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1737287 ·
Last close
$2.12
Market Cap
$731.73M
52W High
$4.46
52W Low
$1.84
ADV30
11,051,987
Next earnings
2026-08-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -46,092,000 | -42,607,000 | 395,958,000 | 30,309,000 | 117,083,000 |
| Dec 2025 | 0 | — | -42,404,000 | -38,810,000 | 415,905,000 | 51,688,000 | 123,363,000 |
| Sep 2025 | 0 | — | -44,901,000 | -41,400,000 | 439,771,000 | 37,815,000 | 124,442,000 |
| Jun 2025 | 0 | — | -54,437,000 | -50,943,000 | 470,593,000 | 52,332,000 | 126,032,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-149,246,000
Investing CF
$95,559,000
Financing CF
$30,157,000
CapEx
$-643,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.87
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,010,709,000
Inventory
—
Receivables
—
ST Investments
$198,522,000
EBIT TTM
$-189,811,000
Pretax Income TTM
$-190,886,000
Interest Exp TTM
$1,075,000
Analysts
12
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -206,933,000 | -190,886,000 | 415,905,000 | 123,363,000 | — | -149,246,000 |
| Dec 2024 | 22,000 | -257,482,000 | -257,590,000 | 548,710,000 | 126,531,000 | — | -200,300,000 |
| Dec 2023 | 95,000 | -314,492,000 | -327,265,000 | 642,837,000 | 130,604,000 | — | -237,733,000 |
| Dec 2022 | 156,000 | -335,536,000 | -340,414,000 | 821,579,000 | 154,697,000 | — | -220,519,000 |
TTM Snapshot
Revenues TTM
$120,000
NetIncome TTM
$-289,979,000
OpCashFlow TTM
$0
Assets (Latest)
$548,710,000
Forward EPS
$-0.77
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VOR | Vor Biopharma Inc. | $764.02M | $14.10 | — |
| AURA | Aura Biosciences, Inc. | $786.77M | $7.61 | — |
| SLDB | Solid Biosciences Inc. | $677.33M | $6.88 | — |
| SANA | Sana Biotechnology, Inc. | $848.79M | $3.05 | — |
| CABA | Cabaletta Bio, Inc. | $606.56M | $3.72 | — |
News headlines (Yahoo Finance, 1h cache)
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
2026-05-26 12:30 · Yahoo
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1
2026-05-14 14:17 · Yahoo
Big Pharma’s 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
2026-05-14 13:20 · Yahoo
Allogene Therapeutics Inc (ALLO) Q1 2026 Earnings Call Highlights: Promising Trial Results and ...
2026-05-14 05:00 · Yahoo
Allogene Therapeutics Q1 Earnings Call Highlights
2026-05-14 00:13 · Yahoo
Allogene Therapeutics Q1 2026 Earnings Call Transcript
2026-05-13 22:12 · Yahoo
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
2026-05-13 20:02 · Yahoo
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
2026-05-06 12:30 · Yahoo
William Blair Initiates Natera (NTRA) With Outperform
2026-05-02 14:35 · Yahoo
Allogene Therapeutics (ALLO) Closes $200.4M Public Offering of Common Stock
2026-05-01 09:23 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.